Report Archive
All Research
Page 6 of 43 · 1027 reports
38/100
Coeur Mining: A Stronger Seven-Mine Platform, No Longer Cheap Enough to Ignore the Cycle
Coeur Mining is a North American precious-metals producer whose earnings now come from seven mines spanning gold, silver and, after the March 2026 New Gold deal, copper. Q1 2026 brought record adjusted EBITDA of 474.9 million USD and 340.8 million USD of operating cash flow, ending the quarter in a net-cash position, but 2026 guidance rests on aggressive metal-price assumptions of 4,550 USD per ounce gold and 77.50 USD per ounce silver. Rating Hold: the platform is far stronger than before Rochester, SilverCrest and New Gold, yet at 16.54 USD the price already assumes high metals and smooth integration, leaving no margin of safety against normalization.
45/100
Bio-Rad Laboratories: A Company in Transition, Priced Without a Margin of Safety
Bio-Rad is a diversified life-science tools and clinical-diagnostics supplier whose core operations generated 2.58 billion USD of 2025 sales, complicated by an unusually large Sartorius AG stake that dominates its GAAP earnings. Q1 2026 brought a 527.1 million USD net loss driven by a 727.7 million USD fair-value drop on the Sartorius stake, even as the operating business still produced 108.1 million USD of operating cash flow, and management cut full-year currency-neutral revenue guidance to a range of -3.0% to +0.5%. Rating Hold: durable niche assets and real asset backing, but at 297.09 USD the price already assumes the 2026 slowdown is manageable and leaves no margin of safety.
42/100
Mowi ASA: A License-Constrained Salmon Platform at a Fair, Not Forgiving, Price
Mowi is the world's largest and most geographically diversified Atlantic salmon farmer, controlling the full chain from feed and genetics through farming, processing and branded sales across more than 70 countries. Q1 2026 revenue hit a record EUR 1.544 billion even as operational EBIT per kg fell to EUR 1.62 from EUR 1.98 a year earlier, and the June 2026 sale of the loss-making Canada East unit to Cooke for CAD 225 million signals a pivot from chasing tonnes toward cleaner regional returns. Rating Hold: scale and integration are real advantages, but at roughly 16.8x underlying EPS the stock offers too little margin of safety against biology, Norwegian tax risk and weak-region drag.
46/100
Guardant Health: A Rerating Built on a Company in Transition
Guardant Health is a blood-based oncology diagnostics company whose economic center still sits in advanced-cancer therapy selection while its upside narrative has shifted toward Shield, a colorectal-cancer screening test that just won UnitedHealth coverage for 100 million lives. 2025 revenue reached 982 million USD, up 33% year on year, with non-GAAP gross margin improving from 62% to 66%, yet the company still posts negative owner earnings and trades near 17x forward EV/sales, above larger and cash-generative peer Natera. Rating Watch: an excellent liquid-biopsy franchise, but the stock already prices in broad Shield adoption and a faster profit path than has been proven, with the ideal buy zone at 68 to 74 dollars.
U.S. Market Close Daily | 2026-07-01
U.S. equities slipped in sector rotation as semiconductor weakness outweighed firmer breadth and financial-sector support.
39/100
Aker Solutions: A Leaner Contractor Priced Without a Margin of Safety
Aker Solutions is a Norwegian offshore-energy contractor that has become measurably leaner since folding its subsea business into the OneSubsea joint venture in 2023, with earnings driven mainly by offshore oil-and-gas project execution and life-cycle services rather than renewables engineering. FY2025 revenue reached NOK 63.2bn with EBITDA excluding special items of NOK 5.284bn (8.4% margin), but management already guides 2026 revenue down to around NOK 50bn as the Norwegian offshore capex cycle rolls over from its 2025 peak, while renewables and transition work made up only 20% of FY2025 revenue and fell to just 4% of Q1 2026 order intake. Rating Hold: at NOK 44.50 the stock trades inside its acceptable-hold range against a conservative owner-earnings fair value of NOK 26-32, leaving no real margin of safety for a genuinely improved but still cyclical business.
37/100
LONGi Green Energy: A Real Transition, Not Yet a Real Turnaround
LONGi Green Energy is a former monocrystalline-wafer champion pivoting its integrated solar manufacturing business toward back-contact (BC) modules and, since a January 2026 acquisition, early-stage energy storage. In 2025 revenue fell 14.8% to CNY 70.35bn with a CNY 6.42bn attributable net loss, wafers ran a negative 5.30% gross margin, and only the power-station segment stayed solidly profitable, even as BC module shipments reached 22.87GW and rose to 8.34GW of the 12.62GW shipped in the first quarter of 2026. Rating Hold: the balance sheet still holds CNY 53.35bn of cash against CNY 35.20bn of debt, but at CNY 13.12 the stock already prices in a successful transition that the financials have not yet delivered.
41/100
Estun Automation: A Good Company at a Bad A-Share Price
Estun Automation is a Chinese full-stack industrial-automation group whose robot and intelligent-manufacturing-systems business now supplies 81.8% of 2025 revenue and grew 31.8% year on year, even as the legacy automation-components segment shrank 8.7%. Gross margin has only partly recovered to 29.5%, the top five customers took 37.2% of nine-month 2025 revenue, and the Shenzhen line trades above a 250x trailing P/E, roughly 2.5 times richer than the newly listed Hong Kong shares on a per-share basis. Rating Watch: domestic share gains and a stronger post-listing balance sheet are real, but the A-share price already discounts a cleaner margin and cash-conversion story than the filings currently support.
44/100
KINGSEMI: A Scarce Domestic Track Asset, Priced Well Ahead of the Evidence
KINGSEMI is a specialized Chinese semiconductor-equipment maker in front-end coat/develop tracks and single-wafer wet tools, now controlled by NAURA. 2025 revenue grew 11% to CNY 1.95 billion, but attributable profit fell 65% to CNY 71.7 million, and a one-month 79% surge lifted the market cap to CNY 88.5 billion, about 45 times sales. Rating Avoid: a genuinely scarce front-end track franchise, but at CNY 439 the price already assumes a mature cleaning-and-platform business the operating evidence does not yet support.
41/100
Mitsubishi Electric: A Conglomerate in Transition, Fully Priced
Mitsubishi Electric is a diversified Japanese electrical group earning from factory automation, infrastructure, HVAC and building systems, semiconductors and defense, with FY2026 revenue of ¥5.9 trillion. All five segments grew profit in FY2026 and management is pushing ROIC-based reform, ¥280 billion of cross-shareholding sales and a richer service mix, yet free cash flow of ¥231.5 billion still trails net profit of ¥407.7 billion while the stock has rerated to around 30x trailing earnings. Rating Hold: business quality and capital discipline are genuinely better, but at ¥5,858 the price already discounts much of the reform before cash conversion catches up, leaving little margin of safety.
51/100
Meituan: A High-Quality Franchise With Temporarily Broken Earnings
Meituan is China's largest local-services platform, monetizing food delivery, in-store and hotel services, and instant retail, with 2025 revenue of RMB364.9 billion. A subsidy war with Alibaba and JD flipped Core Local Commerce from RMB52.4 billion of 2024 operating profit into a loss and pushed the group to a RMB23.4 billion net loss in 2025, even as platform GTV and transaction volume kept growing. Rating Hold: the franchise stays high-quality and the balance sheet strong, but at HK$68.50 the shares lack a clear margin-of-safety cushion until Core Local Commerce proves post-war profitability can stick.
U.S. Market Close Daily | 2026-06-30
U.S. stocks closed higher in high-level consolidation as AI-chip leadership and improving late breadth offset higher Treasury yields.
52/100
Anji Microelectronics: A High-Quality Compounder, but a Better Company Than Stock
Anji Microelectronics is China's leading CMP-slurry maker, supplying semiconductor polishing slurries and a widening platform of formulated wet electronic chemicals, with 2025 revenue of CNY 2.50bn (up 36%) and a disclosed global CMP-slurry share that climbed from about 7% in 2022 to 13% in 2025. The usage story is genuine: attributable net profit grew 47% to CNY 784m and functional wet chemicals surged 64%, yet after a roughly 161% one-year run the stock trades near CNY 305, about 88 times 2025 earnings, a price that already capitalizes years of flawless execution. Rating Watch: a real hard-tech compounder, but currently a better company than stock, with a serious re-underwriting zone only back at CNY 190-230.
U.S. Market Close Daily | 2026-06-29
U.S. stocks rebounded sharply from a five-day slide as AI and semiconductor leadership returned, but narrow breadth kept the tape in an oversold-rebound state.
42/100
Schaeffler: More Interesting Than Its Multiple, but Not Yet Safer Than It Implies
Schaeffler is a German motion-technology supplier (bearings, automotive aftermarket, and electrification systems), reshaped into a four-division group after the 2024 Vitesco merger, with 2025 revenue of EUR 23.5 billion. The legacy bearings and aftermarket businesses are better than the stock's distressed-supplier multiple implies, but E-Mobility still ran a -16% adjusted EBIT margin in 2025 and EUR 4.9 billion of net debt keeps the group below investment grade, so the cheap multiple reflects real transition risk rather than hidden value. Rating Watch: buy only at a larger discount (ideal entry EUR 6.2-6.9) or after clearer proof that E-Mobility losses and leverage are turning.
42/100
Beijing Jingyi: A Genuine Semiconductor Subsystem Business at an Increasingly Demanding Price
43/100
TechnipFMC: A Higher-Quality Subsea Franchise Now Priced for Continued Delivery
TechnipFMC is a focused subsea production-systems and SURF contractor whose earnings are anchored by a record offshore order book. A 16.57 billion USD backlog, free cash flow that doubled to 1.45 billion USD, and a swing to net cash have re-rated it from a post-merger cleanup story into a cyclical-quality franchise. Rating Hold: a genuinely better subsea business, but at 64.44 USD the price already discounts most of the backlog and cash-conversion improvement, leaving a thin margin of safety.
50/100
UCB SA: A Specialty-Biopharma Growth Platform That Has Already Re-Rated
UCB is a Belgian specialty biopharma in immunology and neurology, and BIMZELX is now its largest product at €2.227 billion of 2025 net sales. FY2025 revenue rose 26% to €7.741 billion, adjusted EBITDA jumped to €2.636 billion, and the balance sheet swung from €1.454 billion of net debt to roughly net cash; yet at €258.50, about 24x forward earnings, the price already embeds much of the BIMZELX and portfolio ramp. Rating Hold: a genuinely stronger company at a price that leaves essentially no margin of safety for fresh capital.
38/100
Hecla Mining: A Cleaner, Debt-Free Silver Major Still Priced Without a Margin of Safety
Hecla Mining is North America's largest silver producer, now a debt-free, three-mine platform (Greens Creek, Lucky Friday, Keno Hill) that turned the 2025 cyclical upswing into 1.423 billion USD of sales and 310.2 million USD of free cash flow. Asset quality and the balance sheet have genuinely improved, but at 15.54 USD the stock already discounts most of that, and the upside is driven by silver-price beta rather than durable compounding. Rating Hold: a cleaner, better-run silver major worth holding, with no margin of safety for new money until it falls toward the 10-11 USD ideal-buy zone.
42/100
Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent
Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
36/100
Panasonic Holdings: Better Business, Priced Ahead of Proof
Panasonic Holdings is a diversified Japanese electronics group whose earnings base is still mature B2B and appliance operations, while batteries and AI-infrastructure products drive the growth narrative. FY2026 sales were ¥8.05 trillion across six segments, but ROE fell to 3.8% on ¥174.5 billion of restructuring charges, and the shares are up about 68% in 2026 on an AI-infrastructure rerating that capitalizes one hot battery-and-data-center engine across the whole group. Rating Hold: the business mix is genuinely improving, but at ¥4,540 the price already discounts most of the battery, AI-infrastructure, and restructuring upside, leaving no margin of safety against a conservative fair value near ¥2,400-¥2,690.
47/100
Symrise: A High-Quality Compounder Now Priced for Delivery, Not Discovery
Symrise is a scaled, oligopolistic flavors-and-fragrances and nutrition platform that gets paid for being embedded in customers' everyday products, with 2025 sales of €4.93 billion, a 21.9% adjusted EBITDA margin and record €780 million of business free cash flow. The 2026 question is delivery, not discovery: organic growth has cooled from 8.7% in 2024 to low single digits in 2025 and slightly negative in Q1 2026, yet cash conversion, leverage and margin quality all improved, so the franchise is intact while the near-term growth premium is not obviously earned. Rating Hold: a high-quality compounder whose €88.16 price already reflects most of the self-help and recovery, with a more comfortable margin of safety only in the high-€50s to mid-€60s.
47/100
JD.com: A Stronger Retail Core Discounted for the Cost of Transition
JD.com is China's largest self-operated online retailer, built on a supply-chain-first model spanning first-party retail, marketplace services, logistics, health and industrial procurement. Its retail core is strengthening, with JD Retail operating margin up to 5.6% in Q1 2026 and net service revenue growing 20.6% against just 1.0% product growth, yet group profit and cash conversion are obscured by heavy food-delivery and overseas investment, while listed-subsidiary stakes worth about US$17.7 billion anchor a sum-of-the-parts case. Rating Cautious Buy: the market discounts the cost of transition more than it credits a stronger retail core, large buybacks and visible listed stakes.